In trials investigating the use of extended release calcifediol in patients with CKD, the dosages utilized (30–90 μg/day) resulted in very high 25(OH)D levels, with successive PTH reduction until 25(OH)D levels exceeded 125 nmol/l (50 ng/ml) without any apparent toxicity [116, 117]. This evidence concerns the gene PTH and chronic kidney disease.